NASDAQ:GBT
Delisted
GLOBAL BLOOD THERAPEUTICS Stock News
$68.49
+0 (+0%)
At Close: Jan 27, 2023
New filing by GLOBAL BLOOD THERAPEUTICS, INC. POLITICAL ACTION COMMITTEE (GBT PAC)
02:30pm, Tuesday, 14'th Dec 2021 The FEC
The GLOBAL BLOOD THERAPEUTICS, INC. POLITICAL ACTION COMMITTEE (GBT PAC) successfully filed their F1N with a confirmation ID of FEC-1551570 *********CommitteeId: C00788661 | FilingId: 1551570 | FormType: F1N | CoverageFrom: | CoverageThrough: | ReportType: *********
GBT Announces Proposed Offering of $250.0 Million of Convertible Senior Notes
12:28pm, Tuesday, 14'th Dec 2021 Intrado Digital Media
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it intends to offer $250.0 million aggregate principal amount of its Convertible Senior Notes due 2028 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). GBT also intends to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $37.5 million aggregate principal amount of notes (the “additional notes”). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Global Blood Therapeutics Stock (GBT): Why The Price Increased
08:35am, Tuesday, 14'th Dec 2021
The stock price of Global Blood Therapeutics Inc (NASDAQ: GBT) increased by 5.33% in the most recent trading session. This is why it happened.
Hedge Funds Are Coming Back To Global Blood Therapeutics Inc (GBT)
06:46pm, Monday, 13'th Dec 2021 Insider MonkeyGlobal Blood Therapeutics (NASDAQ:GBT) Sees Unusually-High Trading Volume
04:58pm, Monday, 13'th Dec 2021 Dakota Financial News
Global Blood Therapeutics, Inc. (NASDAQ:GBT) shares saw unusually-high trading volume on Monday . Approximately 31,713 shares changed hands during trading, a decline of 97% from the previous sessions volume of 1,096,170 shares.The stock last traded at $28.00 and had previously closed at $27.59. GBT has been the topic of several research reports. Jefferies Financial Group []
Global Blood Therapeutics, Inc. (NASDAQ:GBT) Given Consensus Recommendation of Buy by Brokerages
04:54pm, Sunday, 12'th Dec 2021 Dakota Financial News
Global Blood Therapeutics, Inc. (NASDAQ:GBT) has received a consensus rating of Buy from the sixteen analysts that are currently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12 month price objective among brokerages that []
Zacks: Analysts Anticipate Global Blood Therapeutics, Inc. (NASDAQ:GBT) Will Announce Quarterly Sales of $55.05 Million
07:34am, Saturday, 11'th Dec 2021 Transcript Daily
Brokerages predict that Global Blood Therapeutics, Inc. (NASDAQ:GBT) will post sales of $55.05 million for the current fiscal quarter, according to Zacks. Twelve analysts have issued estimates for Global Blood Therapeutics earnings. The highest sales estimate is $58.00 million and the lowest is $53.00 million. Global Blood Therapeutics reported sales of $41.30 million in the []
Invesco Ltd. Reduces Stock Holdings in Global Blood Therapeutics, Inc. (NASDAQ:GBT)
09:54am, Friday, 10'th Dec 2021 Transcript Daily
Invesco Ltd. trimmed its position in Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 4.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 35,920 shares of the companys stock after selling 1,853 shares during the period. Invesco Ltd. owned about 0.06% of Global Blood Therapeutics worth $1,257,000 []
Global Blood Therapeutics (GBT) GBT 2021 R&D Day
09:33pm, Tuesday, 07'th Dec 2021 Seeking AlphaBenzinga''s Top Ratings Upgrades, Downgrades For December 7, 2021
03:03pm, Tuesday, 07'th Dec 2021 Benzinga
Upgrades For CarMax Inc (NYSE: KMX ), JP Morgan upgraded the previous rating of Neutral to Overweight. For the second quarter, CarMax had an EPS of $1.72, compared to year-ago quarter EPS of $1.79. The stock has a 52-week-high of $155.98 and a 52-week-low of $90.30. At the end of the last trading period, CarMax closed at $144.50. According to Evercore ISI Group, the prior rating for RPM International Inc (NYSE: RPM ) was changed from In-Line to Outperform. In the first quarter, RPM International showed an EPS of $1.08, compared to $1.44 from the year-ago quarter. The current stock performance of RPM International shows a 52-week-high of $99.30 and a 52-week-low of $76.43. Moreover, at the end of the last trading period, the closing price was at $95.43. According to Evercore ISI Group, the prior rating for PPG Industries Inc (NYSE: PPG ) was changed from In-Line to Outperform. In the third quarter, PPG Industries showed an EPS of $1.69, compared to $1.93 from the year-ago quarter. The stock has a 52-week-high of $182.97 and a 52-week-low of $132.10.
IBI Research On Global Blood Therapeutics: Galvanized For Growth
04:14pm, Tuesday, 30'th Nov 2021
Amid the challenging COVID environment, Oxbryta is still generating double-digit sales growth.
What Are You Thinking About Investing In Global Blood Therapeutics Inc. (NASDAQ: GBT) Stock?
03:30pm, Tuesday, 30'th Nov 2021 Stocks Register
Global Blood Therapeutics Inc. (NASDAQ:GBT) traded at $27.98 at close of the session on Monday, 11/29/21, made a downward move of -4.34% on its previous days price. Looking at the stock we see that its previous close was $29.25 and the beta (5Y monthly) reads 1.08 with the days price range being $27.75 $29.79. What Are You Thinking About Investing In Global Blood Therapeutics Inc. (NASDAQ: GBT) Stock? Read More »
$55.29 Million in Sales Expected for Global Blood Therapeutics, Inc. (NASDAQ:GBT) This Quarter
11:06pm, Friday, 26'th Nov 2021 Dakota Financial News
Equities research analysts forecast that Global Blood Therapeutics, Inc. (NASDAQ:GBT) will report sales of $55.29 million for the current quarter, according to Zacks Investment Research. Twelve analysts have made estimates for Global Blood Therapeutics earnings, with the highest sales estimate coming in at $58.00 million and the lowest estimate coming in at $53.00 million. Global []
Zacks: Brokerages Anticipate Global Blood Therapeutics, Inc. (NASDAQ:GBT) Will Announce Earnings of -$1.14 Per Share
11:06pm, Friday, 26'th Nov 2021 Transcript Daily
Analysts expect Global Blood Therapeutics, Inc. (NASDAQ:GBT) to post earnings of ($1.14) per share for the current quarter, Zacks reports. Twelve analysts have issued estimates for Global Blood Therapeutics earnings, with the highest EPS estimate coming in at ($0.94) and the lowest estimate coming in at ($1.42). Global Blood Therapeutics posted earnings of ($1.00) per []
-$1.14 EPS Expected for Global Blood Therapeutics, Inc. (NASDAQ:GBT) This Quarter
05:48pm, Wednesday, 24'th Nov 2021 Transcript Daily
Brokerages forecast that Global Blood Therapeutics, Inc. (NASDAQ:GBT) will announce earnings per share (EPS) of ($1.14) for the current quarter, Zacks Investment Research reports. Twelve analysts have issued estimates for Global Blood Therapeutics earnings, with the lowest EPS estimate coming in at ($1.42) and the highest estimate coming in at ($0.94). Global Blood Therapeutics posted []